Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement in targeted cancer therapy. This novel antibody-drug conjugate joins a monoclonal antigen specifically targeting HER-2 expressing cells with an potent cytotoxic payload, deruxtecan. The process of action incl